Treatment modalities shape infection profiles in advanced lung cancer patients

1 minute, 44 seconds Read



Pulmonary malignancy is one of the most frequent and fatal cancers in elderly patients. Studies have shown that lung cancer patients are more prone to lower respiratory tract infections. This is because these patients usually have airway obstruction, sticky sputum that is not easily coughed up, mucosal surface destruction, and treatment with radiotherapy and chemotherapy. When most patients are diagnosed with lung cancer, they have already developed distant metastases and have lost the opportunity for surgery, therefore, they usually choose to be treated with radiotherapy, chemotherapy and targeted drugs. Radiotherapy and chemotherapy can cause lung injury. Patients who develop pneumonia will delay radiotherapy, which is not conducive to patient prognosis and long-term survival.

Some patients may require chemotherapy alone or may not be able to tolerate radiotherapy, while some patients may be treated with a combination of therapies. Such studies are necessary to clarify the severity and pathogenetic distribution of lower respiratory tract infections in both types of patients and to better focus treatment. Recently, researchers in China analyzed the clinical characteristics and pathogenic data of lower respiratory tract infections in advanced lung cancer patients with different treatment regimens, which were published. Malignancy spectrum.

The researchers found that compared to patients treated with chemotherapy alone, patients treated with combination therapy had higher inflammatory markers (calcitonin, blood sedimentation and hypersensitive C-reactive protein) and were more likely to develop combined infections after lower respiratory infections. Whereas patients treated with standard chemotherapy were more likely to be infected with viruses, those treated with combination therapy were more likely to be infected with gram-negative bacilli. Therefore, it is best to focus on the use of antibiotics and ensure coverage of pathogens in two different treatment regimens in patients with advanced lung cancer. Because infections are more severe in combination therapy patients, it is even more important to complete drug susceptibility testing as early as possible for early intervention.

Source:

Journal Reference:

Guo, R., etc (2023). Clinical characteristics and pathogenic analysis of lower respiratory tract infections in patients with advanced lung cancer with different treatment regimens. Malignancy spectrum. doi.org/10.1002/msp2.17.



Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *